Clinical Trial News and Research

RSS

TASTE trial questions the usefulness of thrombus aspiration after heart attack

Aspiration of the blood clot or "thrombus" that causes a heart attack before re-opening a patient's artery with a balloon catheter does not improve survival compared to performing balloon dilation and stenting alone according to the results of the Thrombus Aspiration in ST- Elevation myocardial infarction in Scandinavia (TASTE) trial.

5 Sep 2013

Study finds similar antibody levels among 4 PCV13 immunization schedules

The use of 4 different 13-valent pneumococcal conjugate vaccine immunization schedules in healthy term infants resulted in no statistically significant differences in antibody levels between the infants after the booster dose at 12 months of age for almost all serotypes, according to a study in the September 4 issue of JAMA.

5 Sep 2013

£13M partnership to accelerate cancer-focused drug discovery launched by Queen's and Almac Discovery

A new -13 million partnership to accelerate cancer-focused drug discovery in Northern Ireland has been launched by Enterprise Minister Arlene Foster MLA.

5 Sep 2013

New laser-based technology may make brain tumor surgery more accurate

A new laser-based technology may make brain tumor surgery much more accurate, allowing surgeons to tell cancer tissue from normal brain at the microscopic level while they are operating, and avoid leaving behind cells that could spawn a new tumor.

5 Sep 2013

Research findings raise hope for new heart therapies

Many people who survive a heart attack find themselves back in the hospital with a failing heart just years later. And the outcome often is unfavorable, owing to limited treatment options. But scientists at Temple University School of Medicine's Cardiovascular Research Center recently found hope in an unlikely source - stem cells in cortical, or compact, bone.

5 Sep 2013

FDA grants Priority Review status to Takeda's investigational drug vedolizumab for ulcerative colitis

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., today announced that the United States Food and Drug Administration has granted Priority Review status for the Biologics License Application for its new investigational drug vedolizumab for the treatment of adults with moderately to severely active ulcerative colitis.

5 Sep 2013

Affinium initiates dosing in Phase 1 IV clinical trial of antibiotic prodrug, AFN-1720

Affinium Pharmaceuticals announced today that it has initiated dosing in a Phase 1 intravenous clinical trial of its new antibiotic prodrug, AFN-1720. AFN-1720 is the prodrug of the active drug, AFN-1252.

5 Sep 2013

RVX-208 drug fails to increase good cholesterol levels in ASSURE trial

Patients with coronary artery disease and low levels of "good cholesterol - or high-density lipoprotein - who were treated with a drug designed to increase HDL levels and reduce coronary plaque build-up, experienced no better results than those treated with placebo, according to research conducted by the Cleveland Clinic Coordinating Center for Clinical Research.

4 Sep 2013

Removing of carotid body appears to be effective for high blood pressure

Removing one of the tiniest organs in the body has shown to provide effective treatment for high blood pressure. The discovery, made by University of Bristol researchers and published in Nature Communications, could revolutionise treatment of the world's biggest silent killer.

4 Sep 2013

Scientists identify new drugs that have potential to slow down progression of Parkinson's

New drugs which may have the potential to stop faulty brain cells dying and slow down the progression of Parkinson's, have been identified by scientists in a pioneering study which is the first of its kind.

4 Sep 2013

AQUARIUS trial data shows Aliskiren reduced incidents of death, stroke, heart attack

Patients with clogged and hardened arteries who already have their blood pressure under control may benefit from an additional blood pressure-lowering medication, according to research from the Cleveland Clinic Coordinating Center for Clinical Research (C5Research).

4 Sep 2013

Viralytics releases financial results for 2013

Viralytics Limited (ASX:VLA, OTCQX:VRACY) has released its financial results for the year ended 30 June 2013.

3 Sep 2013

Apitope successfully completes ATX-MS-1467 Phase I trial in relapsing MS patients with positive results

Apitope, the drug discovery and development company focused on treating the underlying cause of autoimmune diseases, today announced completion with positive results of its second Phase I clinical trial of ATX-MS-1467.

3 Sep 2013

Prana's PBT2 drug recognised as one of the most promising treatments under development

Prana Biotechnology, a leading global developer of first-in-class treatments for neurodegenerative disease, is pleased to announce Elsevier Business Intelligence has named clinical drug PBT2 as one of the Top 10 Neuroscience Projects to Watch.

3 Sep 2013

Imaxio's pro-immunogenic technology used in tuberculosis vaccine phase I clinical study

Imaxio, a biopharmaceutical company specializing in vaccines and genomics, announces today that IMX313, its proprietary pro-immunogenic technology, has been administered for the first time in humans in a tuberculosis vaccine phase I clinical study. The trial is being conducted by the Jenner Institute at Oxford University, England.

3 Sep 2013

Argininosuccinic aciduria (ASA) and gene therapy: an interview with Dr Julien Baruteau, UCL Institute for Women's Health, London

This rare genetic condition can theoretically affect patients at any age but symptoms are more often observed in childhood and even uncommonly during the first days of life.

2 Sep 2013

Longer looks: Lack of cancer vaccines, misleading nutrition labels, should women pay more than men for insurance?

Six years from now, when my daughter turns 11, she will get a three-part human papillomavirus vaccine that will reduce her chances of getting cervical cancer by around 70 percent.

30 Aug 2013

BP and headache drug effectively speeds up treatment of TB

Infectious disease experts at Johns Hopkins have found, in studies in mice, that a drug better known as a treatment for high blood pressure and headaches effectively speeds up treatment of TB when added to the standard, daily antibiotic regimen. Test animals were cured in four months instead of the usual six.

30 Aug 2013

Protein activated by inflammation converts glioblastoma multiforme cells to most aggressive form

A prominent protein activated by inflammation is the key instigator that converts glioblastoma multiforme cells to their most aggressive, untreatable form and promotes resistance to radiation therapy, an international team lead by researchers at The University of Texas MD Anderson Cancer Center reported online today in the journal Cancer Cell.

30 Aug 2013

Albumin-bound paclitaxel has favorable risk–benefit profile in NSCLC

Albumin-bound paclitaxel plus carboplatin is an effective and well-tolerated first-line treatment in patients with advanced non-small-cell lung cancer, irrespective of histology, study results show.

29 Aug 2013

Clinical Trial News and Research

TASTE trial questions the usefulness of thrombus aspiration after heart attack

Study finds similar antibody levels among 4 PCV13 immunization schedules

£13M partnership to accelerate cancer-focused drug discovery launched by Queen's and Almac Discovery

New laser-based technology may make brain tumor surgery more accurate

Research findings raise hope for new heart therapies

FDA grants Priority Review status to Takeda's investigational drug vedolizumab for ulcerative colitis

Affinium initiates dosing in Phase 1 IV clinical trial of antibiotic prodrug, AFN-1720

RVX-208 drug fails to increase good cholesterol levels in ASSURE trial

Removing of carotid body appears to be effective for high blood pressure

Scientists identify new drugs that have potential to slow down progression of Parkinson's

AQUARIUS trial data shows Aliskiren reduced incidents of death, stroke, heart attack

Viralytics releases financial results for 2013

Apitope successfully completes ATX-MS-1467 Phase I trial in relapsing MS patients with positive results

Prana's PBT2 drug recognised as one of the most promising treatments under development

Imaxio's pro-immunogenic technology used in tuberculosis vaccine phase I clinical study

Argininosuccinic aciduria (ASA) and gene therapy: an interview with Dr Julien Baruteau, UCL Institute for Women's Health, London

Longer looks: Lack of cancer vaccines, misleading nutrition labels, should women pay more than men for insurance?

BP and headache drug effectively speeds up treatment of TB

Protein activated by inflammation converts glioblastoma multiforme cells to most aggressive form

Albumin-bound paclitaxel has favorable risk–benefit profile in NSCLC

eBook: Using iPSCs models for human disease research and drug discovery eBook

Latest eBooks

Editorial Focus eBook - Proteomics (2nd Edition)

Industry Focus eBook - Life Science Microscopy (2nd Edition)

Biologics stability screening toolkit: Three practical workflows for accelerating formulation development

Event guide: 2nd World RNA-Based Therapeutics & Vaccines Summit Korea

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery